A new slow-release implant has shown unprecedented success in wiping out bladder cancer in more than 80 percent of patients, ...

The treatment of bladder cancer could see a major advancement thanks to an innovative drug delivery approach. This targeted ...

Growth hormone receptor (GHR) signaling in bladder cancer is associated with advanced tumor stages and poor survival outcomes. High GHR expression in tumors up-regulates genes involved in drug ...

Patients with initially low- or intermediate-risk primary tumors will often have a high-risk recurrence before progressing to more advanced disease, whereas primary high-risk tumors typically show ...

Learn the symptoms of bladder cancer —blood in the urine, pain, and irritation or obstruction when urinating —and when to see a healthcare provider.

A slow drug-release system has proven highly effective in treating certain bladder cancer patients whose tumors were previously unresponsive to therapy. A new targeted drug delivery system known as TA ...

Breast cancer advancements include targeted therapies, oral medications for ER-positive/HER2-negative populations, and ...

ESMO 2025 bladder cancer highlights include results from KEYNOTE-905/EV-303, RC48-C016, and IMvigor011 studies.

What Is Zusduri Used For? Zusduri is used to treat a certain type of recurrent, persistent bladder cancer known as LG-IR-NMIBC. About 75% of people with bladder cancer present with non-muscle invasive ...

On Thursday, Aura Biosciences, Inc. (NASDAQ:AURA) revealed early data from an ongoing Phase 1 trial of bel-sar (AU-011) in patients with non-muscle-invasive bladder cancer (NMIBC). To date, the trial ...

TAR-200, a small drug-releasing implant, wiped out tumors in most patients with high-risk bladder cancer. Its slow, ...